# Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

> **NCT02610075** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 62 (actual)

## Conditions studied

- Locally Advanced Solid Tumours
- Metastatic Solid Tumours
- Ovarian Cancer

## Interventions

- **DRUG:** AZD1775

## Key facts

- **NCT ID:** NCT02610075
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-01
- **Primary completion:** 2018-04-26
- **Final completion:** 2018-04-26
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02610075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02610075, "Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02610075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*